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Background/aim: Quarter of colorectal cancer patients have a family history and 6% of these comprise hereditary cancer syndromes.
For developing national health strategies for genetic screening, it is crucial to determine the spectrum of damaging alterations in
causative genes and to describe frequent founder mutations.
Materials and methods: One hundred and thirty six unrelated colorectal cancer cases were investigated. Qiagen large hereditary cancer
panel and Hereditary Cancer Solution v1.1 panel were used for sequencing. The sequencing process was performed on the Illumina
MiSeq system. The data analyses were performed on QIAGEN Clinical Insight (QCI™) Analyze software and Sophia DDM software.
Results: Of 136 patients, 11 (8%) were found to carry a pathogenic and 2 (1.4%) were found to carry a likely pathogenic mutation.
Altogether, 12 different pathogenic and likely pathogenic mutations were detected.
Conclusion: This study is the first study in Turkish colorectal cancer patients using next-generation sequencing. Point mutation
screening in the families of patients with mutations will be able to identify individuals at risk in a cost-effective manner.
Key words: Colorectal cancer, genetics, hereditary cancer, next-generation sequencing

1. Introduction
Colorectal cancer (CRC) is the third most common cancer
among both sexes and the fifth leading cause of cancer
death in Turkey. According to the guidelines, 60% of CRC
deaths could be prevented with screening. Approximately,
25% of people diagnosed with CRC have a family history
and 6% of these comprise hereditary cancer syndromes for
which deleterious genomic variations are found in cancer
susceptibility genes. Therefore, the hereditary component
of CRC becomes more important when compared to other
cancers [1].
Hereditary CRC is divided into two groups as
nonpolyposis syndromes and polyposis syndromes [2].
Hereditary nonpolyposis colorectal cancer (HNPCC)
accounts for 83% of hereditary colorectal cancers, which
is also known as Lynch syndrome. Lynch syndrome is
inherited in an autosomal dominant pattern, caused by
mutations in mismatch repair genes. Mainly mutations of
MLH1, MSH2, PMS2, and MSH6 genes, which damage
the mismatch repair mechanism, are responsible for the
disease [3]. Microsatellite instability (MSI) analysis is an
alternative for evaluating HNPCC at somatic level. High-

level MSI (MSI-H) is a diagnostic marker for HNPCC.
Moreover, somatic BRAF mutations and germline MLH1
hypermethylation have diagnostic value. An individual
carrying a germline MLH1 or MSH2 mutation is estimated
to have a cumulative lifetime cancer risk of up to 74% and
40% for CRC and endometrial cancer, respectively [4,5].
Development of multiple adenomatous polyps
throughout the gastrointestinal tract is characterized
for familial adenomatous polyposis (FAP). Without
precaution, the risk of developing CRC in FAP patients
by the age of 40 is 100%. Mutations of APC gene are
responsible for FAP [6]. Prevalence of FAP is approximately
1 in 10,000 individuals and accounts for 0.5–1% of all
CRC cases [7]. FAP can cause papillary thyroid cancer and
hepatoblastoma as well as CRC.
MUTYH-associated polyposis (MAP), PeutzJeghers syndrome (PJS), juvenile polyposis (JPS), and
Cowden syndrome are the other rare CRC predisposition
syndromes. The clinical features of MAP are similar to that
of FAP but while hundreds of thousands of polyps are seen
in FAP, this number is between 5 and 100 in MAP. Mean
age at diagnosis of MAP patients is also higher than FAP.
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Biallelic pathogenic variants of MUTYH gene can cause the
disease [8]. PJS is characterized by benign hamartomatous
polyps in the gastrointestinal tract and hyperpigmented
macules on the lips and oral mucosa. The hamartomatous
polyps in PJS are most commonly located in the small
intestine but may also occur along jejunum and ileum.
The risk of CRC, and breast, pancreatic, stomach, testical,
ovarian, lung, and cervical cancer is increased in these
patients. STK11 is the causative gene of PJS. Prevalence of
PJS is estimated nearly 1 in 100,000 individuals [9]. JPS
is a rare autosomal dominant disease, identified by the
presence of hamartomatous polyps in the digestive tract
and increased cancer risk of CRC, gastric, and pancreatic
cancers. Disease-causing genes are SMAD4 and BMPR1A
for this syndrome. JPS has a prevalence of approximately
1 in 100,000 [10]. Cowden syndrome is also characterized
by multiple hamartomatous lesions, particularly in skin,
gastrointestinal tract, breast, and thyroid gland. Breast
and thyroid cancers are the most expected neoplasms
for Cowden syndrome. PTEN gene mutations have been
described in these groups of patients [11]. According
to recent publications, germline pathogenic variants in
POLD1, POLE, and GREM1 have been associated with
CRC tendency [12,13].
Sanger sequencing of cancer susceptibility genes one by
one was not widespread in routine diagnosis because it was
time-consuming and not cost-effective. With the spread
of next-generation sequencing (NGS)-based hereditary
cancer panels, high-throughput sequencing was made
possible, databases of different populations have been
constructed, and the spectrum of cancer predisposition
genes has been provided. In case of insufficient diagnostic
ability of these panels, whole exome/genome sequencing
and transcriptome studies have been brought to the agenda
[14]. With the new genes discovered as a result of research,
the content of hereditary cancer panels is expanding day
by day.
The prevalence of cancer susceptibility gene
mutations varies with ethnicity and region. There may
be contradictory views about the pathogenic potential
of the variants. In order to make a clear interpretation,
it is important to provide genetic counseling in the light
of detailed clinical information of the patient. Although
data from different populations presented with databases
and articles continues to increase day by day, the majority
of studies include the prevalence and mutation spectrum
cancer susceptibility genes in European, Asian, North
American, African, and African–American populations
[14,15]. Hereby, there is a need for better understanding
the mutation spectrum of these genes and cancer risk
prediction in Turkish people. For developing national health
strategies for genetic screening, it is crucial to determine
the spectrum of damaging alterations in causative genes
and to describe frequent founder mutations.
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2. Materials and methods
2.1. Patients and samples
A total of 136 subjects were included in the present
study at University of Health Sciences, Dr. Abdurrahman
Yurtaslan Ankara Oncology Training and Research
Hospital, Medical Genetics Clinic, between 2017 and 2019.
Ethical committee of Dr. Abdurrahman Yurtaslan Ankara
Oncology Training and Research Hospital approved
the study (2019-11/443). Written informed consent was
obtained from all patients before testing for the use of
their DNA samples for research purposes. Family histories
were recorded for all the patients, including first-, second-,
and third-degree relatives on both the maternal and
paternal sides of the family, and covering at least three
generations. Personal and clinical data (sex, age of onset,
histopathologic characteristics, immunohistochemistry,
and pathology results) were taken from an inspection of
digital medical archive. All the patients were unrelated
and provided genetic testing criteria in agreement with
the National Comprehensive Cancer Network (NCCN)
Guidelines for Genetic/Familial High-Risk Assessment:
Colorectal.
2.2. DNA extraction
Blood samples were collected into EDTA tubes. Patients’
DNAs were extracted with QIAcube® automated DNA
isolation system (Qiagen Inc. Mississauga, ON, Canada).
Isolated DNA samples were stored at –20 °C. Before
sequencing, the DNA concentration and quality were
measured with NanoDrop (ND-1000) spectrophotometer
(Nano-Drop Technologies, Wilmington, DE, USA) for
OD260/OD280, 1.8 to 2.0.
2.3. Genetic testing
Qiagen large hereditary cancer panel (Qiagene, Hilden,
Germany) and Hereditary Cancer Solution v1.1 panel
(Sophia Genetics, Saint‐Sulp) were used for sequencing.
The sequencing process was performed on the Illumina
MiSeq system (Illumina Inc., San Diego, CA, USA). The
data analyses were performed on QIAGEN Clinical Insight
(QCI™) Analyze software (QIAGEN, Hilden, Germany)
for Qiagen large hereditary cancer panel and Sophia DDM
software (Sophia Genetics, Saint‐Sulp) for Hereditary
Cancer Solution v1.1 panel. The gene content of these
hereditary cancer panels was listed in Table 1. Sanger
validation was performed for homopolymer regions, low
quality variants, insertions and/or deletions, splice site
alterations, and novel variants.
2.4. Variant classification
The recent ACMG/AMP guideline for standardized
variant interpretation in Mendelian disorders was used
for classification. Pathogenic variants are well-established
disease- causing DNA changes in in-house database
and/or literature. The main evaluation criteria are
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represented by strong clinical findings and family history,
independent confirmatory observations, and supporting
pathogenicity functional studies. Likely pathogenic
variants are considered the probable cause of the disease,
or the effect on the protein function is predicted to be
likely deleterious (>90% probability to cause the disease).
Variant of uncertain significance (VUS) alterations are
genetic variants with unknown or questionable impact
on the disease. These variants are typically very rare and
predicted to be deleterious.
3. Results
Of the 136 patients, 11 (8%) were found to carry a
pathogenic and 2 (1.4%) were found to carry a likely
pathogenic mutation. Altogether, 12 different pathogenic
and likely pathogenic mutations were detected. The
pathogenic and likely pathogenic variations were located
in ATM, BRCA2, CHEK2, MLH1, MSH2, MUTYH,
PMS2, RINT1, and TP53 genes. MUTYH:c.884C>T
(NM_001128425) pathogenic variation is the only

pathogenic/likely pathogenic variant, described in more
than one patient. One patient was biallelic, and the other
patient was monoallelic with another pathogenic variant,
MUTYH:c.536A>G, at transposition. This compound
heterozygous patient was also the only pathogenic
compound heterozygous patient of this study (Table 2).
VUS alteration was detected in 40 patients (29.4%)
with 38 different variants (Table 3). The spectrum of
pathogenic and likely pathogenic mutations comprises 2
(15.3%) frame-shift variants, 4 (30.7%) nonsense variants,
4 (30.7%) missense variants, 1 (7.7%) splice site defect, 1
(7.7%) inframe variant, and 1 (7.7%) synonymous variant
(Table 2). The spectrum of VUS variants comprises
37 (92.5%) missense variants and 3 (7.5%) splice site
alteration (Table 3). All the pathogenic, likely pathogenic,
and VUS variants are listed in Tables 2 and 3.
4. Discussion
With the expansion of precision medicine, analysis
of cancer-related genes at both germline and somatic

Table 1. Gene content of hereditary cancer panels.

Qiagen Qiaseq
Hereditary Custom
Cancer Panel

AIP, APC, ATM, ATR, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CDH1,
CDK4, CDKN2A, CHEK2, CTNNA1, EPCAM, FAM175A, FANCC, FLCN, GALNT12, GEN1, GPC3,
GREM1, HOXB13, MET, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NTHL1, PALB2, PALLD,
PIK3CA, PMS1, PMS2, POLD1, PRSS1, PTCH1, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RET,
RINT1, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TP53, VHL, XRCC2

Sophia Hereditary
Cancer Solution Panel

ATM, APC, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FAM175A, MLH1, MRE11A,
MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, PMS2CL, PTEN, RAD50, RAD51C, RAD51D,
STK11, TP53, XRCC2

Table 2. Described pathogenic and likely pathogenic variants in CRC patients.
Gene

Transcript

cDNA change

Protein change

dbSNP

Consequence Variant type

n

ATM

NM_000051

c.7788G>A

p.Glu2596=

rs587780639

Synonymous

Pathogenic

1

BRCA2

NM_000059

c.9317G>A

p.Trp3106Ter

rs80359205

Nonsense

Pathogenic

1

CHEK2

NM_007194

c.1260C>A

p.Cys463Ter

rs762205611

Nonsense

Pathogenic

1

MLH1

NM_000249

c.1609C>T

p.Gln537*

rs63751277

Nonsense

Pathogenic

1

MSH2

NM_000251

c.2362dupA

p.Thr788Asnfs*11

rs63750463

Frameshift

Pathogenic

1

MUTYH

NM_001128425

c.536A>G

p.Tyr179Cys

rs34612342

Missense

Pathogenic

1

MUTYH

NM_001128425

c.545G>A

p.Arg182His

rs143353451

Missense

Pathogenic

1

MUTYH

NM_001128425

c.884C>T

p.Pro295Leu

rs374950566

Missense

Pathogenic

2

MUTYH

NM_001128425

c.14734_1439delGGA p.Glu480del

-

In frame

L.Pathogenic

1

PMS2

NM_000535

c.690_691delGT

p.Phe231Trpfs*17

rs1064795447

Frameshift

Pathogenic

1

RINT1

NM_021930

c.1333+1G>A

-

rs375350359

Splice defect

L.Pathogenic

1

TP53

NM_001276696

c.37C>T

p.Gln13Ter

-

Nonsense

Pathogenic

1

L.Pathogenic: likely pathogenic
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Table 3. Described VUS variants in CRC patients.
Gene

Transcript

cDNA change

dbSNP

Consequence

n

APC

NM_000038

c.2438A>G

rs201522866

Missense

1

APC

NM_000038

c.3920T>A

rs1801155

Missense

2

APC

NM_000038

c.5609A>G

rs1189738231

Missense

1

ATM

NM_000051

c.2021A>G

rs201762714

Missense

1

ATM

NM_000051

c.6869A>C

-

Missense

1

ATM

NM_000051

c.7082T>C

rs1169558907

Missense

1

ATM

NM_000051

c.3402+16A>G

rs63382531

-

1

BARD1

NM_000465

c.586A>G

rs376259263

Missense

1

BLM

NM_000057

c.11T>C

rs144706057

Missense

1

BRCA1

NM_7294

c.3448C>T

rs80357272

Missense

1

BRCA1

NM_7294

c.4342A>G

rs80357486

Missense

1

BRCA2

NM_000059

c.5070A>C

rs56087561

Missense

1

BRCA2

NM_000059

c.5092T>C

-

Missense

1

BRCA2

NM_000059

c.5495C>A

rs138489917

Missense

1

BRIP1

NM_032043

c.1255C>T

rs150624408

Missense

1

BRIP1

NM_032043

c.3178G>A

rs149016505

Missense

1

BUB1B

NM_001211

c.522A>G

-

Missense

1

CDH1

NM_004360

c.184G>A

rs587781898

Missense

1

CDH1

NM_004360

c.2387G>A

rs587782549

Missense

1

CDH1

NM_004360

c.2359G>A

rs766270336

Missense

1

CDH1

NM_004360

c.2595G>C

rs778019174

Missense

1

CHEK2

NM_007194

c.944G>A

-

Missense

1

CHEK2

NM_007194

c.1556G>T

rs587780180

Missense

1

EPCAM

NM_002354

c.28G>C

rs863224709

Missense

1

MLH1

NM_000249

c.1876T>C

rs377241633

Missense

1

MRE11A

NM_005591

c.818C>G

rs143400546

Missense

1

MSH2

NM_000251

c.-107C>A

rs587782649

-

1

MSH2

NM_000251

c.435T>G

rs63750124

Missense

2

MSH2

NM_000251

c.2606C>A

rs730881772

Missense

1

MUTYH

NM_001128425

c.821G>A

rs149866955

Missense

1

PALB2

NM_024675

c.3201+4delA

-

-

1

PMS1

NM_000534

c.2722T>A

-

Missense

1

PMS2

NM_000535

c.2392T>C

-

Missense

1

POLD1

NM_001256849

c.455C>T

rs41563714

Missense

1

POLD1

NM_001256849

c.2293G>A

rs759190487

Missense

1

RAD50

NM_005732

c.2651G>A

rs558302979

Missense

1

RET

NM_020975

c.224C>T

rs142641173

Missense

1

RET

NM_020975

c.628G>A

rs1060500762

Missense

1

levels will become even more important in diagnosis,
susceptibility, prognosis, treatment resistance, and
recurrence assessments. In this context, Dr. Abdurrahman
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2017, germline hereditary cancer panel tests have been
performed in our molecular genetics laboratory within the
scope of public health services.
With four pathogenic, one likely pathogenic, and
one VUS changes, the most reported gene in our study
was MUTYH, but as it was mentioned before, only the
biallelic damaging variants can cause MAP (Tables 2 and
3). Among these six samples only MUTYH:c.884C>T
(NM_001128425) variant was biallelic (homozygous
for one patient and compound heterozygous for one
patient). Previously, this variant was observed in
both the homozygous and compound heterozygous
state in individuals affected with MAP [16,17]. Two
pathogenic mutation carriers (MUTYH:c.536A>G
(NM_001128425),
MUTYH:c.545G>A
(NM_001128425)) and one likely pathogenic mutation
carrier (MUTYH:c.1437_1439delGGA) had not sufficient
evidence for explaining the molecular etiology of MAP.
Copy number variations (CNVs) can complete the second
hit. Although the bioinformatics pipelines allow us to
evaluate the CNVs, the gold standard genetic test for
detecting CNVs is multiplex ligation-dependent probe
amplification analysis (MLPA). Until now, a gross (>4.2
kilobase) deletion covering exons 4-16 has been described
in three MAP patients from Spain, France, and Brazil,
indicating a possible southern European founder variant
[18–20]. An exon 15 deletion has also been reported
recently [21]. Therefore, MLPA should be performed for
excluding second hit missing for MUTYH gene in these
samples, but MLPA for MUTYH gene was not available for
this study. In different context, there are also studies about
the effect of monoallelic MUTYH mutations on CRC risk.
Although not as high penetrance as in biallelic cases, the
increased risk of CRC has also been reported in MUTYH
mutations in monoallelic cases [22]. Pedigrees of the cases
of this study also support this thesis. Further investigation
is needed for exploring the risk levels between biallelic and
monoallelic cases to give an effective genetic counseling to
affected individuals.
Among the syndromes causing CRC, the most
common one is Lynch syndrome (HNPCC) in the patients
included in this study. CHEK2:c.1260C>A (NM_007194),
MLH1:c.1609C>T (NM_000249), MSH2:c.2362dupA
(NM_000251), PMS2:c.690_691delGT (NM_000535)
are detected pathogenic variants with HNPCC patients
(Table 2). Although CHEK2 is not a mismatch repair gene
(MMR), mutations of this gene could be responsible for
some cases of Lynch syndrome [23]. The proband, which
carries CHEK2 mutation, has overlapping phenotype
with HNPCC, and the variation meets the pathogenicity
criteria as well. Main genes causing Lynch syndrome are
MSH2 (50%), MLH1 (30–40%), MSH6 (7–10%), PMS2
1

(<5%), and EPCAM (1-3%) respectively [24]. This study
is the first study in Turkish Lynch syndrome patients using
next-generation sequencing technique. For this reason,
there is no study to be referenced about the frequency of
Lynch syndrome mutations in Turkish population. The
frequency of mutations detected among CRCs is relatively
different from the literature, although the sample is not
sufficient to accurately assess this, suggesting that the
distribution of mutations in different populations may also
vary. The mutation spectrum of Lynch syndrome can be
revealed with the consortiums that will be formed by the
collaboration of the centers having data belonging to the
Turkish population. An additional contribution of such
databases would be the healthier reporting of variants
reported as VUS due to lack of in-house data.
The most important cancer type related with BRCA1/2
is breast and ovarian cancer. Other solid tumor cancers
commonly seen in BRCA1/2 carriers are pancreas and
prostate tumors [25]. Although the previous view suggests
that only the BRCA1 gene increases CRC risk, recent
studies suggest that both the BRCA1 and BRCA2 genes
may slightly increase CRC risk [26]. The proband of this
study, with pathogenic BRCA2:c.9317G>A (NM_000059)
variant, was male and support this evidence with the
phenotype and family history. There are two more male
CRC cases in third-degree relatives and there are several
breast cancer cases among both sexes on the pedigree.
Li-Fraumeni syndrome is associated with developing
of several types of cancer, and the germline TP53
mutations are responsible for the phenotype. Pathogenic
TP53:c.37C>T (NM_001276696) mutation detected
in CRC case was also compatible with Li-Fraumeni
syndrome [27]. ATM is altered in 5.58% of all cancers
and CRC is one of the important cancer types in these.
The detected variant, ATM:c.7788G>A (NM_000051),
has synonymous effect and does not cause any amino
acid alteration on the protein. While biallelic mutations
of ATM cause ataxia telangiectasia syndrome, monoallelic
mutations predispose cancer. This variant was described
with both ataxia telangiectasia syndrome and hereditary
cancer [28]. Splice site alteration was detected at in
silico splice site analysis tool, Human Splicing Finder1.
Although the association of RINT1 gene with breast
cancer has been shown, there is no detailed study of its
effect. It has been previously reported that RINT1 may
be associated with Lynch syndrome [29]. A novel splice
variant RINT1:c.1333+1G>A (NM_021930) was detected
in a CRC patient. Although this variant was not seen in the
healthy population, it was found that the splice region was
affected according to Human Splicing Finder. This novel
variant detected in the study is thought to contribute to the
effect of RINT1 mutations on CRC.

http://www.umd.be/HSF/
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In our study, APC gene mutation was not detected in
patients who underwent hereditary cancer panel. Due to
the fact that FAP has distinctive clinical features, single
gene analysis is performed instead of large panels in terms
of cost effectiveness in routine genetic diagnosis. Since
hereditary cancer panels are commercially produced kits,
the patients included in the study were automatically
evaluated for APC gene. Therefore, our study is not
informative in terms of the proportion of FAP patients in
CRC patients and the mutation distribution of the APC
gene.

Hereditary cancer panel application is becoming more
common in patients presenting with a high number of
CRCs or additional cancers in the family. Point mutation
screening in the families of patients with mutations will
be able to identify individuals at risk in a cost-effective
manner. Further studies in Turkish population will
contribute to the spectrum of germline mutations in CRC
patients in the future.
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